RCUS FY 2023 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RCUSArcus Biosciences, Inc.

$2B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$117M+4.5% YoY

Gross Profit

$117M100.0% margin

Operating Income

-$340M-290.6% margin

Net Income

-$307M-262.4% margin

EPS (Diluted)

$-4.15

Cash Flow

Operating Cash Flow

-$306M

Free Cash Flow

-$330M

Stock-Based Comp.

$73M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$633M

Stockholders' Equity

$462M

Cash & Equivalents

$127M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$117M	$112M	+4.5%
Gross Profit	$117M	$112M	+4.5%
Operating Income	-$340M	-$280M	-21.4%
Net Income	-$307M	-$267M	-15.0%